Prospects & Overviews
Pegylated IL-10 induces cancer immunity
The surprising role of IL-10 as a potent inducer of IFN-γ-mediated CD8+ T cell cytotoxicity
Version of Record online: 13 MAY 2013
© 2013 WILEY Periodicals, Inc.
Volume 35, Issue 7, pages 623–631, July 2013
How to Cite
Mumm, J. B. and Oft, M. (2013), Pegylated IL-10 induces cancer immunity. Bioessays, 35: 623–631. doi: 10.1002/bies.201300004
- Issue online: 13 JUN 2013
- Version of Record online: 13 MAY 2013
- cancer immune therapy;
- CD8+ T cells;
- cytotoxic T cells;
- major histocompatibility complex;
Recently, the development of several strategies based on immunotherapy has raised hopes for a more promising way to treat cancer patients. Here, we describe how interleukin (IL)-10, a seemingly unlikely candidate, stimulates the immune system in a particularly efficacious way. IL-10, an omnipotent anti-inflammatory cytokine, delivers an equally potent immune stimulation in the context of CD8+ T cells and tumor immunity. By activation of tumor-resident, tumor-specific CD8+ T cells, pegylated IL-10 can induce rejection of large and metastasizing tumors in mice. Here, we summarize the mechanisms of action of IL-10, the reasons why the mechanisms may be crucial for the treatment of cancer patients, and the rationale for applying pegylated IL-10 in the clinic.